Overview

REMATIB is presented as upadacitinib 15 mg film-coated tablets in a pack of ten tablets, with the indication printed on the carton: adult patients with moderate to severe active rheumatoid arthritis. Upadacitinib is a Janus kinase (JAK) inhibitor engineered to interfere with the JAK-STAT signalling pathway that drives inflammatory cytokine responses in autoimmune disease. For B2B buyers, the procurement question is not whether the molecule works but how to plan MOQ, paperwork, ambient logistics and post-arrival handling so that the product reaches the dispensing pharmacy in specification.

This sourcing walk-through assumes a distributor or institutional buyer ordering a meaningful volume for onward dispensing. It treats the REMATIB carton as the smallest trade unit, the batch certificate of analysis as the key document, and ambient-controlled transport as the default shipping condition for the molecule.

Procurement Workflow and Documentation

Upadacitinib tablets, per FDA labeling and EMA product information, do not require cold-chain refrigeration in their marketed presentation; they are stored at controlled room temperature with excursions monitored. Buyers therefore plan ambient freight with temperature loggers rather than refrigerated containers. The batch documentation chain typically includes the certificate of analysis from the manufacturer, the GMP statement, and where applicable the import licence and product registration certificate in the destination country.

Minimum order quantity depends on the supplier. A new distributor typically starts with a pilot shipment of several cartons to confirm demand before scaling, while established hospital channels order by pallet. The 15 mg by 10 tablet pack size is convenient for unit-of-use dispensing and reduces the risk of counting errors at the pharmacy bench. Buyers should match MOQ to local prescribing volume, considering that upadacitinib is a chronic-therapy product and patients may remain on treatment for months per clinician guidance.

Storage, Shelf Life and Last-Mile Handling

The labelled shelf life and storage condition are the binding numbers for inventory planning. B2B warehouses should hold REMATIB away from excessive humidity, since the film-coat protects the active layer; relative humidity in storage should remain within the range stated on the product label. Once received, batch segregation by expiry date allows first-expiry-first-out rotation. Damaged or repacked units should be quarantined and not returned to saleable stock without manufacturer guidance.

FAQ

Q: Does REMATIB require refrigerated shipping? A: No. Per FDA labeling for upadacitinib tablets, the product is stored at controlled room temperature; ambient freight with temperature monitoring is sufficient.

Q: What is the smallest trade unit? A: The smallest trade unit is the 15 mg by 10 tablet carton. Pallets are typically configured by stacking sealed shippers, with the number of cartons per pallet defined by the supplier.

Q: Which documents should the buyer request from the supplier? A: At minimum: certificate of analysis, batch release certificate, GMP certificate and any destination-country product registration. Import permits vary by jurisdiction and must be confirmed locally.

Q: How should the distributor plan MOQ for a new account? A: Begin with a pilot order sized to cover the first two to four weeks of prescribing volume, then scale based on demand realised. Avoid over-ordering given the chronic-therapy nature of the product.